NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") (NASDAQ:RVPH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980
The investigation concerns whether Reviva and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On April 15, 2024, Revival disclosed in a filing with the U.S. Securities and Exchange Commission that "[o]n April 12, 2024, the Audit Committee . . . of the Board of Directors . . . concluded that the Company's previously issued financial statements for the fiscal year ended ...